SG11201402554SA - Responsiveness to angiogenesis inhibitors - Google Patents

Responsiveness to angiogenesis inhibitors

Info

Publication number
SG11201402554SA
SG11201402554SA SG11201402554SA SG11201402554SA SG11201402554SA SG 11201402554S A SG11201402554S A SG 11201402554SA SG 11201402554S A SG11201402554S A SG 11201402554SA SG 11201402554S A SG11201402554S A SG 11201402554SA SG 11201402554S A SG11201402554S A SG 11201402554SA
Authority
SG
Singapore
Prior art keywords
responsiveness
angiogenesis inhibitors
angiogenesis
inhibitors
Prior art date
Application number
SG11201402554SA
Other languages
English (en)
Inventor
Peter Carmeliet
Haas Sanne Lysbet De
Diether Lambrechts
Stefan Scherer
Original Assignee
Hoffmann La Roche
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Vib Vzw, Life Sciences Res Partners Vzw filed Critical Hoffmann La Roche
Publication of SG11201402554SA publication Critical patent/SG11201402554SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
SG11201402554SA 2011-11-23 2012-11-19 Responsiveness to angiogenesis inhibitors SG11201402554SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11190229 2011-11-23
PCT/EP2012/072953 WO2013076029A1 (en) 2011-11-23 2012-11-19 Responsiveness to angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
SG11201402554SA true SG11201402554SA (en) 2014-06-27

Family

ID=47215557

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402554SA SG11201402554SA (en) 2011-11-23 2012-11-19 Responsiveness to angiogenesis inhibitors

Country Status (14)

Country Link
US (2) US20150004136A1 (ko)
EP (1) EP2783015A1 (ko)
JP (1) JP2014533956A (ko)
KR (1) KR20140096073A (ko)
CN (1) CN104066852A (ko)
AR (1) AR088939A1 (ko)
AU (1) AU2012342682A1 (ko)
CA (1) CA2854568A1 (ko)
IL (1) IL232573A0 (ko)
MX (1) MX2014006186A (ko)
RU (1) RU2014123166A (ko)
SG (1) SG11201402554SA (ko)
WO (1) WO2013076029A1 (ko)
ZA (1) ZA201403447B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015096049A (ja) * 2013-11-15 2015-05-21 凸版印刷株式会社 Ｖｅｇｆ阻害剤長期奏功性予測方法
EP3328746B1 (en) * 2015-07-31 2020-06-03 Graphic Packaging International, LLC Carton with dispenser, blank and method for forming the same
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5604099A (en) 1986-03-13 1997-02-18 Hoffmann-La Roche Inc. Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5310893A (en) 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
US4851331A (en) 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
DE68928853T2 (de) 1988-05-20 1999-08-05 Cetus Corp Befestigung von sequenzspezifischen proben
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5137806A (en) 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69128520T2 (de) 1990-10-31 1998-07-09 Tosoh Corp Verfahren zum Nachweis oder Quantifizierung von Zielnukleinsäuren
IE913930A1 (en) 1990-11-13 1992-06-17 Siska Diagnostics Nucleic acid amplification by two-enzyme, self-sustained¹sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP0540997A1 (en) 1991-11-05 1993-05-12 F. Hoffmann-La Roche Ag Methods and reagents for HLA class I DNA typing
JP2001507921A (ja) 1992-04-27 2001-06-19 トラスティーズ オブ ダートマス カレッジ 生物学的液体中の遺伝子配列の検出
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
GB0004232D0 (en) * 2000-02-24 2000-04-12 Zeneca Ltd Diagnostic method
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2462242B1 (en) * 2009-08-04 2015-04-01 F.Hoffmann-La Roche Ag Responsiveness to angiogenesis inhibitors

Also Published As

Publication number Publication date
JP2014533956A (ja) 2014-12-18
AU2012342682A8 (en) 2014-09-11
CA2854568A1 (en) 2013-05-30
EP2783015A1 (en) 2014-10-01
RU2014123166A (ru) 2015-12-27
US20150004136A1 (en) 2015-01-01
NZ624442A (en) 2016-07-29
CN104066852A (zh) 2014-09-24
US20170066822A1 (en) 2017-03-09
AU2012342682A1 (en) 2014-05-22
AR088939A1 (es) 2014-07-16
ZA201403447B (en) 2015-06-24
MX2014006186A (es) 2014-07-14
WO2013076029A1 (en) 2013-05-30
KR20140096073A (ko) 2014-08-04
IL232573A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
HK1257823A1 (zh) 金屬酶抑制劑化合物
HK1199644A1 (en) Heterocyclylamines as pi3k inhibitors pi3k
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
EP2723731A4 (en) COMPOUNDS INHIBITING METALLOENZYMES
EP2750635A4 (en) REFERENCE TO RELATED APPLICATIONS
EP2755722A4 (en) NEW SGLT INHIBITORS
EP2695315A4 (en) PAGING CONTROL METHOD FOR STATIONARY DEVICES
EP2776393A4 (en) NAMPT INHIBITORS
EP2717689A4 (en) NEW SGLT HEMMER
EP2683411A4 (en) METHODS OF USING MICROARN-26A FOR PROMOTING ANGIOGENESIS
ZA201307496B (en) Novel rock inhibitors
ZA201403447B (en) Responsiveness to angiogenesis inhibitors
IL216798A0 (en) Responsiveness to angiogenesis inhibitors
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201114854D0 (en) Novel rock inhibitors
IL231164A0 (en) Responsiveness to angiogenesis inhibitors
GB201104399D0 (en) Novel inhibitors
GB201120474D0 (en) Inhibitors
GB201100489D0 (en) Improvements relating to retail devices
GB201116456D0 (en) Improvements relating to foorwear
GB201105710D0 (en) Improvements relating to drying devices
FI20110263L (fi) Jaettava kahvakuula